HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oral lichenoid eruption secondary to imatinib (Glivec).

AbstractBACKGROUND:
Oral lichenoid drug eruption (OLE) is a self-restricted inflammatory condition usually secondary to a variety of drugs and dental materials (mercury, gold), and rarely to immunomodulators and new antineoplastic agents such as imatinib mesylate (Glivec). OLE clinical features are reminiscent of lichen planus and include symmetric and asymptomatic, erythematous, reticulated and painful ulcerated plaques. Histological examination reveals perivascular lymphocytic infiltrate and the presence of eosinophils that obscures the dermal-epidermal junction, with acanthosis and mild hyperkeratosis.
METHODS:
A 62-year-old man was treated with Glivec for metastatic gastrointestinal stromal tumour (GIST).
RESULTS:
The patient presented with grey-violaceous plaques on both cheek mucosal surfaces and the lateral sides of the tongue and labial mucosa, with a reticular pattern resembling oral lichen planus. These lesions appeared approximately 1 year after therapy and partially subsided in about 10 weeks, to clear after topical corticosteroids and oral omeprazole. The diagnosis of OLE induced by imatinib was confirmed by histological biopsy evaluation; immunohistochemical analysis revealed intense immunoreactivity with only cytokeratins 5/6 and 14 in the epithelium of affected mucosa. All laboratory investigations proved asiderotic anaemia but excluded infectious causes.
CONCLUSION:
It is believed that this patient developed imatinib-induced OLE; this relationship with therapy rather than the underlying disease rules out a paraneoplastic reaction, and negative immunofluorescence excluded autoimmune dermatosis. In addition, we propose that these lesions are correlated with abnormal expression of some cytokeratins directly caused by this drug.
AuthorsP Ena, F Chiarolini, G M Siddi, A Cossu
JournalThe Journal of dermatological treatment (J Dermatolog Treat) Vol. 15 Issue 4 Pg. 253-5 (Jul 2004) ISSN: 0954-6634 [Print] England
PMID15764042 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
Topics
  • Antineoplastic Agents (adverse effects)
  • Benzamides
  • Drug Eruptions (etiology)
  • Gastrointestinal Stromal Tumors (drug therapy)
  • Humans
  • Imatinib Mesylate
  • Lichenoid Eruptions (chemically induced, diagnosis, therapy)
  • Male
  • Middle Aged
  • Mouth Diseases (chemically induced, diagnosis, therapy)
  • Piperazines (adverse effects)
  • Protein-Tyrosine Kinases (antagonists & inhibitors)
  • Pyrimidines (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: